Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
Primary Purpose
Postpartum Hemorrhage
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Tranexamic Acid
Placebo
Misoprostol
Sponsored by
About this trial
This is an interventional treatment trial for Postpartum Hemorrhage
Eligibility Criteria
Inclusion Criteria:
- Women who delivery vaginally
- Women who experience PPH defined as blood loss ≥700ml
- Women capable of giving consent
Exclusion Criteria:
- Clear contraindication for tranexamic acid such as known allergy or thromboembolic event during pregnancy
- Women delivering via cesarean section
- Provider feels that the woman, at presentation for delivery, is not in a position to give appropriate informed consent
Sites / Locations
- Centre de santé 10ème de Thiès
- Centre hospitalier Régional de Thiès, Ahmadou Sakhir Ndiéguène
- National OB-GYN Hospital
- Hung Vuong Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Tranexamic acid
Placebo
Arm Description
1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
oral placebo + 800 mcg sublingual misoprostol
Outcomes
Primary Outcome Measures
Proportion of women with bleeding controlled with the study regimens alone, without recourse to further treatment in each study arm
Secondary Outcome Measures
Rate of severe PPH
Rate of severe PPH (>1000 ml total blood loss)
Mean/median blood loss
Proportion of women with controlled bleeding
proportion of women with bleeding controlled at different time intervals (20, 40, 60, 120 mins)
Use of uterotonic agents after initial treatment
Proportion of women who are given uterotonic agents after initial treatment
Proportion of women who received a serious interventions
Serious intervention is defined as blood transfusion, interventions for tissue repair, surgical intervention [including curettage, vacuum aspiration for retained placental tissue, hysterectomy, surgical uterine artery ligature])
Proportion of women who received additional drugs
Proportion of women who receive additional drugs
Proportion of women who receive additional intervention
Proportion of women who receive additional interventions (i.e. suturing)
Adverse events
Proportion of women who experience an adverse event
Proportion of women who experience side effects
Proportion of women who experience side effects
Proportion of women who find the treatment tolerable
Proportion of women who find the procedure tolerable and acceptable as indicated in an acceptability scale
Full Information
NCT ID
NCT02805426
First Posted
March 9, 2016
Last Updated
February 15, 2018
Sponsor
Gynuity Health Projects
Collaborators
Center for Research and Consultancy in Reproductive Health
1. Study Identification
Unique Protocol Identification Number
NCT02805426
Brief Title
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
Official Title
Double-blind, Randomized Controlled Trial to Assess the Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
Study Type
Interventional
2. Study Status
Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
October 2016 (undefined)
Primary Completion Date
January 2018 (Actual)
Study Completion Date
January 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gynuity Health Projects
Collaborators
Center for Research and Consultancy in Reproductive Health
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study is a randomized, double-blind, placebo controlled trial that will enroll 250 women (125 per study arm).
The objective of the study is to determine the efficacy and tolerability of oral tranexamic acid when used as an adjunct to misoprostol for treatment of postpartum hemorrhage (PPH). Women will be diagnosed with postpartum hemorrhage if blood loss reaches 700ml in the calibrated receptacle. If diagnosed with postpartum hemorrhage , the woman will be randomized to receive either tranexamic acid or placebo, both in tablet form. All participants will receive 800 mcg sublingual misoprostol (4 tablets 200mcg each).
The investigators hypothesize that tranexamic acid (in tablet form) as an adjunct to misoprostol will be more effective than misoprostol alone in stopping postpartum bleeding without recourse to further treatment in significantly more women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postpartum Hemorrhage
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
260 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Tranexamic acid
Arm Type
Experimental
Arm Description
1950 mg oral tranexamic acid + 800 mcg sublingual misoprostol
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
oral placebo + 800 mcg sublingual misoprostol
Intervention Type
Drug
Intervention Name(s)
Tranexamic Acid
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Type
Drug
Intervention Name(s)
Misoprostol
Primary Outcome Measure Information:
Title
Proportion of women with bleeding controlled with the study regimens alone, without recourse to further treatment in each study arm
Time Frame
20 minutes after initial study treatment
Secondary Outcome Measure Information:
Title
Rate of severe PPH
Description
Rate of severe PPH (>1000 ml total blood loss)
Time Frame
2 hours after delivery
Title
Mean/median blood loss
Time Frame
at two hours after treatment
Title
Proportion of women with controlled bleeding
Description
proportion of women with bleeding controlled at different time intervals (20, 40, 60, 120 mins)
Time Frame
At various time intervals after study treatment (20, 40, 60, 120 mins)
Title
Use of uterotonic agents after initial treatment
Description
Proportion of women who are given uterotonic agents after initial treatment
Time Frame
2 hours after delivery
Title
Proportion of women who received a serious interventions
Description
Serious intervention is defined as blood transfusion, interventions for tissue repair, surgical intervention [including curettage, vacuum aspiration for retained placental tissue, hysterectomy, surgical uterine artery ligature])
Time Frame
2 hours after delivery
Title
Proportion of women who received additional drugs
Description
Proportion of women who receive additional drugs
Time Frame
2 hours after delivery
Title
Proportion of women who receive additional intervention
Description
Proportion of women who receive additional interventions (i.e. suturing)
Time Frame
2 hours after delivery
Title
Adverse events
Description
Proportion of women who experience an adverse event
Time Frame
48 hours after delivery
Title
Proportion of women who experience side effects
Description
Proportion of women who experience side effects
Time Frame
2 hours after delivery
Title
Proportion of women who find the treatment tolerable
Description
Proportion of women who find the procedure tolerable and acceptable as indicated in an acceptability scale
Time Frame
48 hours after delivery
10. Eligibility
Sex
Female
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Women who delivery vaginally
Women who experience PPH defined as blood loss ≥700ml
Women capable of giving consent
Exclusion Criteria:
Clear contraindication for tranexamic acid such as known allergy or thromboembolic event during pregnancy
Women delivering via cesarean section
Provider feels that the woman, at presentation for delivery, is not in a position to give appropriate informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Beverly Winikoff, MD, MPH
Organizational Affiliation
Gynuity Health Projects
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jill Durocher
Organizational Affiliation
Gynuity Health Projects
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dina Abbas, MPH
Organizational Affiliation
Gynuity Health Projects
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Nguyen thi Nhu Ngoc, MD, MSc
Organizational Affiliation
CRCRH
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ayisha Diop, MPH
Organizational Affiliation
Gynuity Health Projects
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre de santé 10ème de Thiès
City
Thiès
Country
Senegal
Facility Name
Centre hospitalier Régional de Thiès, Ahmadou Sakhir Ndiéguène
City
Thiès
Country
Senegal
Facility Name
National OB-GYN Hospital
City
Hanoi
Country
Vietnam
Facility Name
Hung Vuong Hospital
City
Ho Chi Minh City
Country
Vietnam
12. IPD Sharing Statement
Citations:
PubMed Identifier
32143721
Citation
Diop A, Abbas D, Ngoc NTN, Martin R, Razafi A, Tuyet HTD, Winikoff B. A double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for the treatment for postpartum hemorrhage. Reprod Health. 2020 Mar 6;17(1):34. doi: 10.1186/s12978-020-0887-2.
Results Reference
derived
Learn more about this trial
Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage
We'll reach out to this number within 24 hrs